πŸ‡ΊπŸ‡Έ FDA
Patent

US 10577607

Modulation of DYRK1B expression

granted A61KA61K31/7088A61K31/7115

Quick answer

US patent 10577607 (Modulation of DYRK1B expression) held by Ionis Pharmaceuticals, Inc. expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/7088, A61K31/7115, A61K31/712, A61K31/7125